title: [Antiosteoporotic effects of naringenin on ovariectomy-induced osteoporosis in rat].
abstract: To investigate the effect of naringenin on ovariectomy-induced postmenopausal osteoporosis comprehensively and systemically, thirty-two virgin Sprague-Dawley rats about 3-month-old were used and randomly divided into 4 groups: sham control group (Sham), OVX control group (OVX), naringenin treatment group and 17β-estradiol (E2) treatment group. After 12 weeks treatment with different drugs, 24 h urine were collected, organs were weighed and the organ indies were computed. Uterine pathological changes were observed by making paraffin section. Biochemical parameters and bone turnover markers: serum osteocalcin (BGP) and urine deoxypyridinoline (DPD) were analyzed with automatic biochemical analyzer or ELISA assay. Bone mineral density (BMD) and bone mineral content (BMC) were analyzed by DEXA, bone biomechanical properties was measured by three point bending test and the trabecular bone microarchitecture was evaluated by Micro CT. From the results, we can see that: the gaining of weight and the increasing of bone turnover markers such as serum BGP and urinary DPD could be inhibited by naringenin. The treatment could also enhance the bone strength and prevent the deterioration of trabecular microarchitecture, increase the bone volume, trabecular number and thickness, and decrease the trabecular space. The effects mentioned above were not accompanied with stimulating effects on uterus. Long-term using of naringenin had no obvious influence on other organs and the liver and kidney functions. The study suggests that naringenin had obvious antiosteoporotic effect on ovariectomized rats and it had the potential value for the treatment of postmenopausal osteoporosis.
authors.forename: Shuang-Hong
authors.initials: SH
authors.lastname: Song
authors.forename: De
authors.initials: D
authors.lastname: Wang
authors.forename: Yi-Yi
authors.initials: YY
authors.lastname: Mo
authors.forename: Chong
authors.initials: C
authors.lastname: Ding
authors.forename: Peng
authors.initials: P
authors.lastname: Shang
mesh_terms: D000596:Amino Acids / Q000652:urine; D000818:Animals; D015519:Bone Density; D004195:Disease Models, Animal; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D044950:Flavanones / Q000494:pharmacology*; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000188:drug therapy*; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D014599:Uterus / Q000473:pathology
chemical_list: D000596:Amino Acids; D004965:Estrogen Antagonists; D044950:Flavanones; D015675:Osteocalcin; D004958:Estradiol; C036020:deoxypyridinoline; C005273:naringenin